Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

A Novel Risk-Model to Predict Time to First Treatment (TTT) in Chronic Lymphocytic Leukemia Based on Heavy+Light Chain Immunoparesis and Serum Free Light Chain Analysis: Results from the Israeli CLL Study Group

Tamar Tadmor, MD, Andrei Braester, MD, Najib Dally, MD, Ariel Aviv, Yair Herishanu, MD, Mona Yuklea, MD, Lev Shvidel, MD, Naomi Rahimi-Levene, MD, Rosa Ruchlemer, MD, Ariela Arad, MD, Claudia Fogl, MD, Aaron Polliack, MD, Lee Magal, PhD, Kelly Townsend, PhD

Blood (2018) 132 (Supplement 1): 1849.

https://doi.org/10.1182/blood-2018-99-113771

Published: 2018

Journal Articles

Results of a Phase II of Low-Dose Fludarabine and Cyclophosphamide Combined with Standard Dose Rituximab (FCR-LITE) in Elderly, Untreated Patients with Chronic Lymphocytic Leukemia (CLL): The Israeli CLL Study Group Experience

Tamar Tadmor, MD, Yair Herishanu, MD, Andrei Braester, MD, Osnat Bairey, MD, Ariel Aviv, Naomi Rahimi-Levene, MD, Riva Fineman, MD, Itai Levi, MD, Mona Yuklea, MD, Rosa Ruchlemer, MD, Lev Shvidel, MD, Aaron Polliack, MD

Blood (2018) 132 (Supplement 1): 5566.

https://doi.org/10.1182/blood-2018-99-111681

Published: 2018

Journal Articles

Cancer Registries Often Underestimate the True Incidence of CLL

Rosa Ruchlemer, MD, Miri Zatlawi, Yehudit Fishler, Rita Dichtiar, Barbara Silverman, MD MPH, Ariel Aviv, MD, Ariella Arad, MD, Osnat Bairey, MD, Ohad Binyamini, MD, Andre Braester, MD, Riva Fineman, MD, Neta Goldshmidt, MD, Yair Herishanu, MD, Naomi Rahimi-Levene, Lev Shvidel, MD, Tamar Tadmor, MD, Mona Yuklea, MD, Aaron Polliack, MD, Lital Keinan-Boker, MD PhD MPH

Blood (2014) 124 (21): 5646.

https://doi.org/10.1182/blood.V124.21.5646.5646

Published: 2014

Journal Articles

Efficacy and Safety of Frontline Therapy with "FCR" Regimen for Chronic Lymphocytic Leukemia Outside Clinical Trials: Israeli CLL Study Group Experience

Yair Herishanu, MD, Neta Goldschmidt, MD, Osnat Bairey, MD, Rosa Ruchlemer, MD, Riva Fineman, MD, Naomi Rahimi-Levene, Lev Shvidel, MD, Tamar Tadmor, MD, Ariel Aviv, MD, Andrei Braester, MD, Erel Joffe, MDMSc, Aaron Polliack, MD

Blood (2014) 124 (21): 5659.

https://doi.org/10.1182/blood.V124.21.5659.5659

Published: 2014

Journal Articles

Presenting Features and Outcome of Elderly Chronic Lymphocytic Leukemia Patients Diagnosed at the Age of 80 Years or Above. An ICLLSG Study.

Osnat Bairey, Rosa Ruchlemer, MD, Naomi Rahimi-Levene, Yair Herishanu, MD, Andrei Braester, MD, Abraham Klepfish, MD, Lev Shvidel

Blood (2010) 116 (21): 4620.

https://doi.org/10.1182/blood.V116.21.4620.4620

Published: 2010

Journal Articles

Endothelial Function in Patients with Essential Thrombocytosis.

Maya Koren-Michowitz, MD, Batia Avni, MD, Irma Zur, MD, Yulia Volcheck, MD, Naomi Rahimi-Levene, MD, Victor Dishy, MD, Ahuva Golik, MD, Abraham Kornberg, MD

Blood (2005) 106 (11): 3983.

https://doi.org/10.1182/blood.V106.11.3983.3983

Published: 2005

Journal Articles

Chronic Lymphocytic Leukemia Associated with Autoimmune Diseases Often Discloses Activated Phenotype Pattern.

Adrian Duek, MD, Lev Shvidel, MD, Alain Berrebi, Osnat Bairey, MD, Andre Braester, MD, Naomi Rahimi-Levene, MD

Blood (2004) 104 (11): 4802.

https://doi.org/10.1182/blood.V104.11.4802.4802

Published: 2004

Journal Articles

Enhanced Capacity of Monocytes from Patients with Essential Thrombocytemia to Generate Tissue Factor. Possible Mechanism of Thrombosis.

Abraham Kornberg, MD, Maya Koren-Michowitz, MD, Naomi Rahimi-Levene, MD, Yulia Voltchek, MD, Micha Rapoport, MD

Blood (2004) 104 (11): 1937.

https://doi.org/10.1182/blood.V104.11.1937.1937

Published: 2004

Journal Articles

Terrorist Attacks: Transfusion Specialists’ Point of View.

Eldad J. Dann, MD, Lilach Bonstein, PhD, Abraham Kornberg, MD, Naomi Rahimi-Levene, MD

Blood (2004) 104 (11): 4103.

https://doi.org/10.1182/blood.V104.11.4103.4103

Published: 2004

Journal Articles

Association of Protein Z Deficiency with Retinal Artery and Vein Occlusion.

Maya Koren-Michowitz, MD, Eva Eting, MD, Yulia Voltchek, MD, Naomi Rahimi-Levene, MD, Osnat Garach-Jehoshua, PhD, Abraham Kornberg, MD

Blood (2004) 104 (11): 3510.

https://doi.org/10.1182/blood.V104.11.3510.3510

Published: 2004

NARROW

A Novel Risk-Model to Predict Time to First Treatment (TTT) in Chronic Lymphocytic Leukemia Based on Heavy+Light Chain Immunoparesis and Serum Free Light Chain Analysis: Results from the Israeli CLL Study Group

Results of a Phase II of Low-Dose Fludarabine and Cyclophosphamide Combined with Standard Dose Rituximab (FCR-LITE) in Elderly, Untreated Patients with Chronic Lymphocytic Leukemia (CLL): The Israeli CLL Study Group Experience

Cancer Registries Often Underestimate the True Incidence of CLL

Efficacy and Safety of Frontline Therapy with "FCR" Regimen for Chronic Lymphocytic Leukemia Outside Clinical Trials: Israeli CLL Study Group Experience

Presenting Features and Outcome of Elderly Chronic Lymphocytic Leukemia Patients Diagnosed at the Age of 80 Years or Above. An ICLLSG Study.

Endothelial Function in Patients with Essential Thrombocytosis.

Chronic Lymphocytic Leukemia Associated with Autoimmune Diseases Often Discloses Activated Phenotype Pattern.

Enhanced Capacity of Monocytes from Patients with Essential Thrombocytemia to Generate Tissue Factor. Possible Mechanism of Thrombosis.

Terrorist Attacks: Transfusion Specialists’ Point of View.

Association of Protein Z Deficiency with Retinal Artery and Vein Occlusion.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only